George Robison
Urogynecology and Reconstructive Pelvic Surgery · Wilmington, NCNPI 1578520821
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.4%), speaking fees and education — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Mallinckrodt Enterprises LLC at 46.4% of the total. Reporting peaked in 2019 at $4,130 and has fallen 92.2% since, to $322 in 2025.
Across 216 payments — averaging $35.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$4K
- AbbVie$1K
- Pfizer$524
- Medtronic$418
- Astellas Pharma US Inc$329
- Hologic Sales And Service, LLC$173
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$3,52046%
- Food & beverage$3,97152%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 2 | $3,520 |
| AbbVie(2 entities) | 73 | $1,080 |
| Pfizer | 27 | $524 |
| Medtronic(2 entities) | 17 | $418 |
| Astellas Pharma US Inc | 18 | $329 |
| Hologic Sales And Service, LLC | 9 | $173 |
| Minerva Surgical, Inc | 2 | $153 |
| Novo Nordisk | 8 | $136 |
| Myovant Sciences Inc. | 6 | $123 |
| Aspira Women's Health Inc | 3 | $108 |
| Coloplast | 6 | $100 |
| Lilly USA, LLC | 5 | $97 |
| Urovant Sciences Inc | 4 | $77 |
| AMAG Pharmaceuticals, Inc. | 4 | $72 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Boston Scientific | 3 | $58 |
| Axonics, Inc. | 2 | $48 |
| Johnson & Johnson | 1 | $44 |
| Smith+Nephew | 2 | $43 |
| Avion Pharmaceuticals | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Astellas Pharma Global Development | 1 | $30 |
| Vertex | 1 | $30 |
| KARL Storz Endoscopy-america | 1 | $28 |
| Evofem Biosciences, Inc. | 2 | $27 |
| Intuitive Surgical | 1 | $26 |
| Mayne Pharma Commercial LLC | 1 | $25 |
| Exeltis, USA Inc. | 1 | $24 |
| Provepharm Inc. | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Osiris Therapeutics Inc. | 1 | $15 |
| Coopersurgical, Inc. | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFIRMEV$3,520
- Endometrial Ablation System (Device)$143
- COLOGUARD$121
- INTERSTIM$119
How this compares
$7,582 in reported general payments places this provider in the 60th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.
See all urogynecology and reconstructive pelvic surgery providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 76 | $63,052 |
| MyrbetriqMirabegron | 40 | $28,945 |
| Estradiol | 201 | $19,191 |
| BotoxOnabotulinumtoxina | 16 | $9,839 |
| YuvafemEstradiol | 19 | $4,714 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 265 | $2,736 |
| ProgesteroneProgesterone, Micronized | 24 | $1,011 |
| Doxycycline Hyclate | 56 | $365 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $305 |
| Metronidazole | 21 | $269 |
| Fluconazole | 45 | $228 |
| Ondansetron OdtOndansetron | 33 | $190 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 21 | $173 |
| NitrofurantoinNitrofurantoin Macrocrystal | 13 | $148 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 47 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $65 | $63,05276 claims |
| Astellas Pharma US IncMyrbetriq | $329 | $28,94540 claims |
| AbbVieBotox | $1,080 | $9,83916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.
Other urogynecology and reconstructive pelvic surgery in Wilmington
- Cary FishburneCharlotte$231K
- William PorterCharlotte$157K
- Catherine MatthewsWinston Salem$70K
- Erinn MyersCharlotte$30K
- Nazema SiddiquiDurham$29K
- Amie KawasakiDurham$27K
- Cindy AmundsenDurham$19K
- Rahul DuttaWinston Salem$13K
- Sarah BradleyCary$11K
- Kevin SteppCharlotte$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.